Mizuho analyst Anthony Petrone raised the firm’s price target on Cooper Companies to $400 from $390 and keeps a Buy rating on the shares. The analyst sees a favorable sentiment setup heading into the Q1 results for medtech and diagnostics companies. A sentiment shift is being driven by a steadily improving procedure volume backdrop coupled with less idiosyncratic risk versus other healthcare sub-sectors, the analyst tells investors in a research note. These themes are coupled with a favorable Q1 setup where the combination of conservative guides from earlier in the year against omicron headwinds last year has set up a "low bar" for many names into this upcoming earnings cycle, says the firm.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on COO:
- Cooper Companies price target raised to $430 from $372 at Citi
- Needham med tech analyst to hold an analyst/industry conference call
- Cooper Companies management to meet with Piper Sandler
- Early notable gainers among liquid option names on March 3rd
- Cooper Companies price target raised to $385 from $371 at Baird